We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

129 hedge funds and large institutions have $2.4B invested in Loxo Oncology, Inc in 2017 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 24 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,075% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 4

267% more funds holding in top 10

Funds holding in top 10: 311 (+8)

113% more capital invested

Capital invested by funds: $1.12B → $2.4B (+$1.27B)

104% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 24

50% more funds holding

Funds holding: 86129 (+43)

63% less call options, than puts

Call options by funds: $2.09M | Put options by funds: $5.7M

Holders
129
Holders Change
+43
Holders Change %
+50%
% of All Funds
3.22%
Holding in Top 10
11
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+266.67%
% of All Funds
0.27%
New
47
Increased
49
Reduced
24
Closed
4
Calls
$2.09M
Puts
$5.7M
Net Calls
-$3.62M
Net Calls Change
-$3.62M
Name Holding Trade Value Shares
Change
Change in
Stake
UBS AM
26
UBS AM
Illinois
$19.3M +$3.53M +63,678 +36%
VOYA Investment Management
27
VOYA Investment Management
Georgia
$18.9M +$12.7M +230,054 +3,757%
SAM
28
Sectoral Asset Management
Quebec, Canada
$17.8M +$7.28M +131,405 +145%
Balyasny Asset Management
29
Balyasny Asset Management
Illinois
$17.5M +$702K +12,664 +6%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$14.4M +$2.41M +43,578 +32%
AIC
31
AWM Investment Company
New York
$12.8M -$1.11M -20,000 -11%
BBA
32
Baker Bros. Advisors
New York
$11.1M +$32K +577 +0.4%
Ameriprise
33
Ameriprise
Minnesota
$10.9M +$5.72M +103,142 +316%
CLCM
34
Crawford Lake Capital Management
New Jersey
$10.4M +$7.21M +130,151 New
OM
35
Opaleye Management
Massachusetts
$10.4M
PAMU
36
Pictet Asset Management (UK)
United Kingdom
$9.62M +$11.7M +210,766 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$9.43M +$837K +15,098 +15%
Axa
38
Axa
France
$9.1M -$3.1M -55,925 -33%
FCMI
39
Foresite Capital Management III
California
$9.02M +$693K +12,500 +13%
AAMU
40
Amundi Asset Management US
Massachusetts
$8.15M +$5.63M +101,660 New
SSA
41
Schonfeld Strategic Advisors
New York
$8.02M -$2.6K -47 -0%
Goldman Sachs
42
Goldman Sachs
New York
$7.16M +$2.5M +45,050 +102%
Morgan Stanley
43
Morgan Stanley
New York
$6.99M +$3.1M +55,869 +178%
Charles Schwab
44
Charles Schwab
California
$6.55M +$434K +7,824 +11%
EI
45
EAM Investors
California
$5.95M -$1.61M -29,009 -28%
CS
46
Candriam SCA
Luxembourg
$5.93M -$1.61M -29,000 -28%
USAA
47
United Services Automobile Association
Texas
$5.93M +$181K +3,270 +5%
Prudential Financial
48
Prudential Financial
New Jersey
$5.42M +$3.74M +67,520 New
NIP
49
Nicholas Investment Partners
California
$5.04M +$3.48M +62,810 New
LP
50
LMR Partners
United Kingdom
$4.78M +$3.3M +59,551 New

LOXO Hedge Fund Activity: Q2 2017 in Review

129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q2 2017, worth a combined $2.4B — up 113% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new LOXO positions and 4 closed out — a net gain of 43 holders — while 49 added to existing stakes and 24 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $36.5M. The largest seller was Victory Capital Management, cutting an estimated $29.5M.

  • 129 institutional investors held Loxo Oncology, Inc (LOXO) as of Q2 2017, up from 86 in Q1 2017.
  • Funds reported $2.4B of Loxo Oncology, Inc stock for Q2 2017, up 113% quarter-over-quarter.
  • 47 funds opened new Loxo Oncology, Inc positions in Q2 2017 and 4 closed out, a net change of +43 holders.
  • The largest Loxo Oncology, Inc buyer in Q2 2017 was OppenheimerFunds, an estimated $36.5M added.
  • The largest Loxo Oncology, Inc seller in Q2 2017 was Victory Capital Management, an estimated $29.5M sold.

Based on aggregated 13F filings for Q2 2017.